IMC Immuron Ltd
- 0.089
- 0.0000.00%
Immuron Ltd News
Immuron Says Jeannie Joughin Was Appointed to Board >IMRN
Immuron Says Jeannie Joughin Was Appointed to Board >IMRN
Immuron Says Roger Aston Has Resigned From Board of Directors
Immuron Says Roger Aston Has Resigned From Board of Directors
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%
Immuron (ASX:IMC) saw a 51% surge in global sales in the March quarter compared with the prior comparative period, driven by a strong performance of its Travelan product in Australia, according to a W
ADRs Close Lower, Immuron Ltd. Declines 17.1%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed lower on Monday, as the S&P/BNY Mellon index
We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate
Immuron Shares Soar Premarket on Positive Travelan Study
By Colin Kellaher U.S.-listed shares of Immuron more than doubled in premarket trading Thursday after the biopharmaceutical company reported positive results from a Phase 2 study of its Travelan prod
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials
Immuron (ASX:IMC) confirmed the efficacy of its single-dose Travelan drug in preventing moderate to severe diarrhea induced by Escherichia coli (E. coli) bacteria, the company said in a Wednesday fili
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January
Immuron (ASX:IMC) said sales of its Travelan immune supplement reached AU$2.7 million in the year to date ending January, a Tuesday filing said. Sales of the over-the-counter immune supplement for pat
Press Release: Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron CEO, Steven Lydeamore Investor Webinar Presentation MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrat
Immuron Posts Record Travelan Sales in Fiscal H1
Immuron (ASX:IMC) reported record sales of AU$2.3 million from its over-the-counter gastrointestinal and digestive health immune supplement Travelan for the first half of fiscal year 2024. This brough
Immuron Reports Big Jump in Fiscal Q1 Travelan Sales
Immuron (ASX:IMC) reported a big jump in Travelan sales in the fiscal first quarter ended June. Sales jumped year over year to AU$1.6 million in fiscal Q1, up AU$1.5 million from the year-ago quarter'
Immuron Limited Announces Participation in the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 11:00 PTMelbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceu
Immuron Sees Nearly 8000% Boost in August Sales of Gastrointestinal Drug
Sales of Immuron's (ASX:IMC) gastrointestinal and digestive health supplement Travelan rose by a substantial 7984% in August to around AU$1.2 million from AU$14,581 during the year-ago period. The pos
Planet MicroCap Review Magazine for Summer 2023 Now Online
LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / Planet MicroCap, a global multimedia financial news and publishing company that focuses on delivering news, information, data and analytics for publicl
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%
Immuron (ASX:IMC) secured a good manufacturing practice clearance from the Australian medical regulator Therapeutic Goods Administration related to the packaging used for the biopharmaceutical firm's
Immuron Ltd Owned Ateria Health Launches Juvia in Australia
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the tr
Immuron FY23 Sales A$1.80M >IMRN
Immuron FY23 Sales A$1.80M >IMRN
Immuron FY23 Sales Increase 136% on FY22 Sales
MELBOURNE, Australia, July 05, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales (unaudited net sales) results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan and Protectyn.
Immuron (ASX:IMC) Sees Global Sales Boost of 136pc in FY23
Immuron Limited Announces Participation in the LD Micro Invitational XIII
Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset
Analysis
Price Target
No Data
